Legend Biotech (LEGN) Other Non-Current Assets (2020 - 2026)
Legend Biotech's (LEGN) quarterly Other Non-Current Assets came in at $26.5 million in Q1 2026, up 374.66% YoY from $5.6 million in Q1 2025, and up 113.71% on a QoQ basis from $12.4 million in Q4 2025.
Legend Biotech (LEGN) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 7 years of Other Non-Current Assets data on file, last reported at $26.5 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 374.66% year-over-year to $26.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.5 million (up 374.66% YoY) and the FY2025 annual result came in at $12.4 million, down 4.62% from the prior year.
- Other Non-Current Assets climbed to $26.5 million in Q1 2026, from $12.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $26.5 million in Q1 2026 to a low of $1.1 million in Q1 2023.
- A 5-year average of $7.4 million and a median of $1.9 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 618102.36% — and 2023, when it sank 95.69%.
- Tracing LEGN's Other Non-Current Assets over 5 years: stood at $1.5 million in 2022, then rose by 0.4% to $1.5 million in 2023, then soared by 770.73% to $13.0 million in 2024, then retreated by 4.62% to $12.4 million in 2025, then soared by 113.71% to $26.5 million in 2026.
- The last three Other Non-Current Assets figures came in at $26.5 million (Q1 2026), $12.4 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 25.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.50 Mn |
| Mar 31, 2026 | 26.50 Mn |
| Dec 31, 2025 | 12.40 Mn |
| Sep 30, 2025 | 10.99 Mn |
| Jun 30, 2025 | 5.66 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 13.00 Mn |
| Sep 30, 2024 | 1.93 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.49 Mn |
| Sep 30, 2023 | 1.53 Mn |
| Jun 30, 2023 | 1.41 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Mar 31, 2022 | 24.62 Mn |
| Dec 31, 2021 | 5.15 Mn |
| Sep 30, 2021 | 4.57 Mn |
| Jun 30, 2021 | 4.89 Mn |
| Mar 31, 2021 | 3,983.00 |